Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review

Visser, Laurenske A.; Louapre, Céline; Groot, Carin A. Uyl–de; Redekop, William K.

doi:10.1016/j.msard.2020.101929

Cited by 26 publications

(34 citation statements)

References 71 publications

(104 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the wish to have children or bear responsibility for a family), pwMS became more active in the decision of switching or discontinuing a DMT. These ndings have previously been recognized by a systematic review on pwMS needs and preferences when making treatment decisions by Visser, Louapre (11). A perceived lack of e cacy might be related to the occurrence of disease activity, but also to the substantial time gap between the act of taking the treatment and the desired outcome being in a distant future [9].…”

Section: Discussionmentioning

confidence: 84%

“…When exploring patients' experiences with DMTs, previous studies have focused on in uencing factors in the decision-making for a DMT, on the use of DMTs [6,9], and decision-making preferences (patientcentred, shared and physician-centred) [5,10,11]. However, a greater insight into patients' individual experiences using DMTs in daily life, for switching and discontinuing DMTs and for deciding not to start treatment with a DMT is under-researched.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patients Experiences with Multiple Sclerosis Disease-Modifying Therapies in Daily Life - a Qualitative Interview Study

Barabasch

Riemann-Lorenz

Scheiderbauer³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Besides coping with a disease with many uncertainties, people with relapsing-remitting multiple sclerosis face complex decisions concerning disease-modifying therapies (DMTs). In an interview study, we aimed to assess patients’ experiences with DMTs. Methods: Problem-centred interviews were conducted with 50 people with relapsing-remitting multiple sclerosis in Germany using maximum variation sampling and covering all licensed DMTs. Data were analysed thematically using deductive and inductive categories. Results: 47 of 50 patients had treatment with at least one of the approved DMTs. The main themes were: 1) starting a DMT, 2) switching to another DMT, 3) discontinuing a DMT, and 4) multiple sclerosis without starting a DMT. Different intercorrelated factors influenced the decision-making processes for or against a DMT. Individual experiences with DMTs in daily life contained the effort in administration, success, and failure of DMTs, coping strategies and well-being without DMTs. The decision-making process for or against a DMT and the use of those treatments can be understood as a constant, continually shifting process, complicated by different factors, which change over time. Experiences with DMTs were characterized by attempts to handle uncertainty and to (re)gain control and integrate adaptivity into one’s life. Conclusion: The study provides a rich and nuanced amount of patients’ experiences with DMTs. The findings demonstrate the importance for practitioners to look at current life circumstances of patients with multiple sclerosis when recommending a DMT and to promote and enable patients to make informed decisions.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Patients Experiences with Multiple Sclerosis Disease-Modifying Therapies in Daily Life - a Qualitative Interview Study

Barabasch

Riemann-Lorenz

Scheiderbauer³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The impact of relapsing-remitting MS patient preferences towards DMTs has begun to be explored in the last decade. A recent systematic review of 31 articles focused on patient preferences for treatments showed that efficacy, mode and frequency of administration, and side-effect profile were the most important attributes [37].…”

Section: Discussionmentioning

confidence: 99%

“…Coast et al found a higher completion rate for the 8-scenario questionnaire (85%) than for the 16-scenario questionnaire (83%) in a randomized, controlled trial to determine the completion rate for conjoint analysis studies [41]. However, the inclusion of fewer DMT attributes could have caused omitted variable bias owing to exclusion of additional key attributes already identified by patients and other healthcare professionals in previous studies, such as mode of administration, side effects, or cost of treatments [12,37]. In addition, there may be other uncollected pharmacist characteristics that could explain differences in terms of preference for DMT options.…”

Section: Discussionmentioning

confidence: 99%

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis

et al. 2020

View full text Add to dashboard Cite

Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was to assess pharmacists´ preferences for DMT efficacy attributes. Methods: A multicenter, non-interventional, cross-sectional, web-based study was conducted. Preventing relapses, delaying disease progression, controlling radiological activity, and preserving health-related quality of life (HRQoL) and cognition were the attributes selected based on a literature review and a focus group with six hospital pharmacists. Conjoint analysis was used to determine preferences in eight hypothetical treatment scenarios, combining different levels of each attribute and ranking them from most to least preferred. Results: Sixty-five hospital pharmacists completed the study (mean age: 43.5 ± 7.8 years, 63.1% female, mean years of professional experience: 16.1 ± 7.4 years). Participants placed the greatest preference on delaying disease progression (35.7%) and preserving HRQoL (21.6%) and cognition (21.6%). Importance was consistent in all groups of pharmacists stratified according to demographic characteristics, experience, research background, and volume of patients seen per year. Conclusions: Understanding which treatment characteristics are meaningful to hospital pharmacists may help to enhance their synergistic role in the multidisciplinary management of patients with MS.

show abstract

“…In these chronic conditions where multiple treatment options exist, and where efficacy and side effects are important in treatment decision-making, route of administration also becomes a key consideration. For example, studies in multiple sclerosis showed route and frequency of administration as two of the most important attributes in treatment decision-making [14,15]. For severe asthma, when patients were asked to rank the importance of attributes when considering biologic treatment options, mode of administration ranked second, only behind out-of-pocket costs [16].…”

Section: Introductionmentioning

confidence: 99%

Hereditary angioedema patients would prefer newer-generation oral prophylaxis

Geba¹,

Sani²,

Gascon³

et al. 2021

Journal of Drug Assessment

View full text Add to dashboard Cite

Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review

Cited by 26 publications

References 71 publications

Patients Experiences with Multiple Sclerosis Disease-Modifying Therapies in Daily Life - a Qualitative Interview Study

Patients Experiences with Multiple Sclerosis Disease-Modifying Therapies in Daily Life - a Qualitative Interview Study

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis

Hereditary angioedema patients would prefer newer-generation oral prophylaxis

Contact Info

Product

Resources

About